Hit a Plateau on Wegovy — and What to Do Next

The week your scales stop moving

You've been losing steadily (maybe a kilogram every fortnight, maybe more in the early weeks) and then, without any obvious explanation, nothing. The number on the scale sits still for two weeks, then three. You haven't changed what you're eating. You're still taking your pen on the same day every week. It feels like the medicine has simply given up on you.

It hasn't. What's happened is that your body has done something it does reliably in response to any sustained period of weight loss: it has recalibrated. A lighter body requires fewer calories to function, so the gap between what you're consuming and what you're burning (the gap that drove those early losses) has quietly closed. This is metabolic adaptation, and it is not specific to Wegovy. It happens with every effective weight-loss approach. The Wegovy treatment page covers what the medicine does and how the licensed titration schedule is designed, which is useful context here.

There is also a misconception worth letting go of gently: many people assume that a plateau means semaglutide has lost its effect in their system, as if the body becomes immune to it. If you want to understand more about what a wegovy plateau actually involves biologically, that page separates the common myths from what the evidence shows. Appetite suppression typically continues; it's the arithmetic that shifts.

What the research actually says about stalling mid-treatment

The STEP 1 trial, published in the New England Journal of Medicine, followed adults on 2.4mg semaglutide for 68 weeks alongside lifestyle intervention. Average weight loss across the group was around 15%. What that headline figure doesn't show is that weight loss is rarely linear: most participants experienced their fastest losses in the first 12 to 20 weeks, followed by a pronounced slowdown as the body settled at a new equilibrium. For a closer look at what hitting a plateau on Wegovy tends to look like in practice, including when it typically occurs and how long it lasts, that page draws on the same trial data in more detail.

Dose plays a role here too. Wegovy begins at 0.25mg and titrates up through several steps to the 2.4mg maintenance dose, with the titration managed by a prescriber over roughly 16 to 20 weeks. Some people plateau before reaching their maintenance dose simply because they are still mid-titration. If you are unsure where you are in the schedule, the NHS medicines page for semaglutide explains the general titration pathway clearly, and your prescriber can confirm your specific plan.

The newer 7.2mg dose, approved by the MHRA in January 2026, has shown around 20.7% average weight loss over 72 weeks in trial data, approaching tirzepatide results. Whether moving to a higher dose is appropriate is a clinical question, not something to self-decide.

The lifestyle factors that quietly reinforce a plateau

Semaglutide reduces appetite significantly, which is one reason it works. It can also make it easier to undereat protein and skip resistance-based activity, both of which contribute to muscle loss. Losing muscle mass lowers your resting metabolic rate further, which deepens the adaptation problem. This is one of the practical trade-offs that a good prescriber will talk through with you. If you want a sense of how Wegovy's timeline typically unfolds, it helps to frame plateaus against the full expected duration rather than month-by-month expectations.

Sleep and stress matter more than most people expect. Elevated cortisol (the stress hormone) makes fat storage, particularly around the abdomen, more stubborn. Poor sleep disrupts ghrelin and leptin signalling, the same appetite hormones that semaglutide partially modulates. Neither factor is something Wegovy can fully override.

Tracking drift is common in longer treatment courses too. Early on, most people are more careful about portions; after several months, habits relax incrementally. If your calorie intake has crept up without you noticing, the plateau is, at least in part, a numbers problem. Reviewing wegovy resultater, which covers the results and outcomes patients actually report across different stages of treatment, can help you benchmark your own progress more realistically. For broader context on whether plateauing on Wegovy is normal, that question is answered in full elsewhere on the site.

How a prescriber approaches a plateau, and what comes next

The right response to a plateau depends on what is causing it, which is why a clinical conversation matters. A prescriber will typically consider: how long the plateau has lasted, what your current dose is, whether your lifestyle factors are contributing, and whether your starting weight-loss target has actually been met even if it doesn't feel that way. Treatment reviews should happen before every repeat prescription, which is a non-negotiable part of safe prescribing. You can read more about our approach on the about us page.

For some people, the right answer is practical: more protein, a slight reduction in highly processed carbohydrates, reintroducing or increasing resistance training. For others, a dose review is warranted. For a small number, the plateau signals that they have reached a stable new weight and the focus should shift to maintaining it. None of those conclusions is reachable without looking at the full picture. If you are weighing up your options more broadly, exploring the weight-loss treatment overview can help put Wegovy in context alongside other licensed approaches.

If you are ready to discuss where you are in your treatment, our prescribers can review your case. Speak to our prescribers through a free consultation at the weight-loss treatments page, a real clinician reads your notes the same day, not software.